Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2025
Track JV activity across pharma and biotech with real-world examples, financial terms, and partnering trends—includes access to contract documents where available.
Unlock Strategic Growth Through Joint Ventures: Models, Partners, and Financials Driving Biopharma Expansion
The Joint Venture Deals in Pharmaceuticals and Biotechnology 2016–2025 report offers an in-depth analysis of strategic joint ventures in the biopharma sector. This comprehensive resource details how companies collaborate through joint ventures to accelerate innovation, enter new markets, and share development risks. Covering agreements announced between 2016 and 2025, the report provides valuable insights into deal structures, financial terms, and partnership strategies.
Free report sample
Key Features & Benefits
✔ Comprehensive Coverage (2016–2025)
Access a detailed compilation of joint venture deals announced over a nine-year period, providing a broad perspective on industry trends.
✔ In-Depth Deal Analysis
Examine the structures and financial terms of joint ventures, including ownership distributions, investment amounts, and governance arrangements.
✔ Financial Benchmarking
Analyze disclosed financial terms to understand investment scales and expected returns, aiding in the assessment of fair market values.
✔ Access to Actual Contract Documents
Benefit from direct links to online copies of actual joint venture contracts filed with the Securities Exchange Commission, offering unparalleled transparency into agreement specifics.
✔ Identification of Active Dealmakers
Identify the top 25 companies most active in joint venture dealmaking, providing insights into potential partners and competitive strategies.
What’s Inside – Chapter Breakdown
Chapter 1: Introduction
An overview of the report's scope, objectives, and the significance of joint ventures in the biopharma industry.
Chapter 2: Trends in Joint Venture Dealmaking
Analysis of emerging patterns, motivations, and strategic benefits driving joint venture formations from 2016 to 2025.
Chapter 3: Structure of Joint Venture Deals
Detailed examination of common structures, governance models, and financial arrangements utilized in joint ventures.
Chapter 4: Leading Joint Venture Deals Since 2016
Profiles of significant joint venture agreements, organized by headline value, with direct links to full contract documents where available.
Chapter 5: Top 25 Most Active Joint Venture Dealmakers
Comprehensive listings of companies with the highest joint venture activity, including summaries and access to detailed deal records.
Chapter 6: Joint Venture Deal Directory
An extensive directory of joint venture deals organized by company A-Z, therapy area, technology type, and industry sector, facilitating targeted research.
Who Should Use This Report?
✅ Corporate Strategy & Business Development Teams
Evaluate joint venture models and identify optimal structures for risk-sharing and market expansion.
✅ C-Level Executives & Investors
Assess strategic alignments and capital efficiencies in joint venture formations to inform investment decisions.
✅ Legal & Transaction Advisors
Benchmark governance structures, equity distributions, and contractual terms to guide negotiations and ensure compliance.
✅ Commercial Operations Teams
Understand how joint venture partners allocate commercialization responsibilities and regional market access.
Why This Report Matters
Joint ventures serve as a strategic intermediary between mergers & acquisitions and licensing agreements, combining financial alignment with collaborative innovation. As biopharma companies seek methods to mitigate development risks, expand geographically, or achieve commercial scale, joint ventures have emerged as a powerful mechanism for long-term value creation. This report elucidates the strategies and partnerships that have shaped successful joint ventures in the industry.
Gain insights from real-world examples. Learn from industry leaders. Structure more effective partnerships.
✔ Comprehensive Coverage (2016–2025)
Access a detailed compilation of joint venture deals announced over a nine-year period, providing a broad perspective on industry trends.
✔ In-Depth Deal Analysis
Examine the structures and financial terms of joint ventures, including ownership distributions, investment amounts, and governance arrangements.
✔ Financial Benchmarking
Analyze disclosed financial terms to understand investment scales and expected returns, aiding in the assessment of fair market values.
✔ Access to Actual Contract Documents
Benefit from direct links to online copies of actual joint venture contracts filed with the Securities Exchange Commission, offering unparalleled transparency into agreement specifics.
✔ Identification of Active Dealmakers
Identify the top 25 companies most active in joint venture dealmaking, providing insights into potential partners and competitive strategies.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in joint venture dealmaking
2.1. Introduction
2.2. Definition of joint venture deal
2.3. Trends in joint venture deals since 2016
2.3.1. Joint venture dealmaking by year, 2016-2025
2.3.2. Joint venture dealmaking by phase of development, 2016-2025
2.3.3. Joint venture dealmaking by industry sector, 2016-2025
2.3.4. Joint venture dealmaking by therapy area, 2016-2025
2.3.5. Joint venture dealmaking by technology type, 2016-2025
2.3.6. Joint venture dealmaking by most active company, 2016-2025
2.4. Reasons for entering into joint venture partnering deals
2.5. The future of joint venture deals
Chapter 3 – Overview of joint venture deal structure
3.1. Introduction
3.2. Joint venture agreement structure
Chapter 4 – Leading joint venture deals
4.1. Introduction
4.2. Top joint venture deals by value
Chapter 5 – Top 25 most active joint venture dealmakers
5.1. Introduction
5.2. Top 25 most active joint venture dealmakers
Chapter 6 – Joint venture deals including contracts directory
6.1. Introduction
6.2. Joint venture deals with contracts 2016-2025
Deal directory
Deal directory – joint venture dealmaking by companies A-Z
Deal directory – joint venture dealmaking by therapy area
Deal directory – joint venture dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of joint venture deal
Figure 2: Trends in joint venture deal announcements, 2016-2025
Figure 3: Joint venture deals signed at each phase of development, 2016-2025
Figure 4: Joint venture deals by industry sector, 2016-2025
Figure 5: Joint venture deals by therapy area, 2016-2025
Figure 6: Joint venture deals by technology type, 2016-2025
Figure 7: Top 25 most active joint venture dealmakers, 2016-2025
Figure 8: Top joint venture deals by value, 2016-2025
Figure 9: Most active joint venture dealmakers, 2016-2025
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
